免疫检查点抑制剂联合化疗治疗难治性高级别B细胞淋巴瘤非特指型1例及文献复习

Treatment of refractory high-grade B-cell lymphoma by immune checkpoint inhibitors combined with chemotherapy:A case report and literature review

目的:回顾性分析1例难治性高级别B细胞淋巴瘤非特指型老年患者应用免疫检查点抑制剂联合化疗的疗效。方法:分析该病例的治疗经过,探讨选择免疫检查点抑制剂联合化疗对难治性高级别B细胞淋巴瘤的作用,并结合相关文献资料进行复习。结果:该例高级别B细胞淋巴瘤非特指型老年患者经过多程化疗后进展,因基础疾病、合并症及化疗耐受性等因素导致后续化疗方案选择受限且疗效欠佳,我们通过联合免疫检查点抑制剂及化疗药物治疗后患者病灶完全消退获得完全缓解,未出现明显毒副反应,无疾病进展时间达半年以上。结论:免疫检查点抑制剂联合化疗是治疗难治性高级别B细胞淋巴瘤有效选择之一。

Objective:To retrospective analyse the efficacy of immune checkpoint inhibitors combined with chemotherapy in an elderly patient with refractory high-grade B-cell lymphoma(non-specific).Methods:Analyze the treatment of this case to investigate the effect of immune checkpoint inhibitors combined with chemotherapy on refractory high-grade B-cell lymphoma,and review in conjunction with relevant literature.Results:This elderly patient with high-grade B-cell lymphoma(non-specific)progressed after multiple courses of chemotherapy.Due to factors such as basic diseases,comorbidities,and tolerance to chemotherapy,the choice of subsequent chemotherapy options was limited and the efficacy was poor.After treating by immune checkpoint inhibitors combined with chemotherapy,the patient's lesions turned to be complete remission,and there was no significant treatment-related adverse reaction.No disease progression time was more than six months.Conclusion:Immune checkpoint inhibitors combined with chemotherapy is one of the effective options for the treatment of refractory high-grade B-cell lymphoma.